Cancer Incidence and Risk Factors Among Immunocompromised Patients
The cancer incidence in certain immunocompromised patients was almost twice as high as the age-adjusted cancer incidence in the general population.
All articles by Jessica Nye, PhD
Monoclonal Antibodies Lower Risk of COVID-19 Hospitalization in Cancer Patients
There was no significant difference in post-infusion hospitalizations between patients with and without a history of cancer.
Perineural Invasion Linked to Biochemical Recurrence After Prostatectomy
Patients with perineural invasion had a 4-fold higher risk of biochemical recurrence.
The Importance of SARS-CoV-2 Genotyping in Clinical Care Settings
The Infectious Diseases Society of America and the American Society of Microbiology formed a committee to review the potential effect of SARS-CoV-2 genotyping in clinical care settings.
Do At-Home Monoclonal Antibody Infusions Decrease the Risk for Hospitalization in High-Risk Patients With COVID-19?
Researchers conducted a study to assess whether an at-home neutralizing monoclonal antibody infusion program decreases the risk for hospitalization among patients with SARS-CoV-2 infection at increased risk for progression to severe disease.
Identifying Patients With Atherosclerotic CVD at Very High Risk for Future Events
Researchers aimed to simplify the process of identifying patients with atherosclerotic cardiovascular disease (ASCVD) at very high risk for future events.
Teprasiran Reduces Risk for Early Acute Kidney Injury After Cardiac Surgery
Researchers sought to evaluate the efficacy and safety of teprasiran for reducing acute kidney injury after cardiac surgery in patients at high risk.
World Health Organization Releases Updated Guidelines on Treatment Strategies for COVID-19
In this fifth update to the living guidelines on drugs for the treatment of COVID-19, the World Health Organization analyzed results of clinical trials that assessed the effects of casirivimab-imdevimab and corticosteroids in patients with severe and non-severe disease.
Cardiac Events With Type 2 Diabetes, Kidney Disease Reduced With Finerenone
Chronic kidney disease increases the risk of cardiovascular events associated with type 2 diabetes. A clinical trial sought to discover if finerenone would help patients with both of these conditions.
Dapagliflozin Reduces Kidney and Cardiovascular Events Among Patients With Chronic Kidney Disease
Investigators report findings from the Dapagliflozin and Prevention of Adverse outcomes in CKD (DAPA-CKD) study.
- Loading...
Loading...
Next post in Chronic Kidney Disease (CKD)
Loading... 
Loading...